-
1
-
-
84875490185
-
Cancer genome landscapes
-
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-58.
-
(2013)
Science
, vol.339
, pp. 1546-1558
-
-
Vogelstein, B.1
Papadopoulos, N.2
Velculescu, V.E.3
Zhou, S.4
Diaz, L.A.5
Kinzler, K.W.6
-
2
-
-
84867878045
-
Cancer stem cell definitions and terminology: The devil is in the details
-
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767-75.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 767-775
-
-
Valent, P.1
Bonnet, D.2
De Maria, R.3
Lapidot, T.4
Copland, M.5
Melo, J.V.6
-
3
-
-
0022544401
-
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
-
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-4. (Pubitemid 16008117)
-
(1986)
Science
, vol.233
, Issue.4760
, pp. 212-214
-
-
Ben-Neriah, Y.1
Daley, G.Q.2
Mes-Masson, A.-M.3
-
4
-
-
0000710215
-
Chromosome studies in human leukemia. II. Chronic granulocytic leukemia
-
Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. JNatl Cancer Inst. 1961;27:1013-35.
-
(1961)
JNatl Cancer Inst
, vol.27
, pp. 1013-1035
-
-
Nowell, P.C.1
Hungerford, D.A.2
-
5
-
-
0015694748
-
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
-
Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-3.
-
(1973)
Nature
, vol.243
, pp. 290-293
-
-
Rowley, J.D.1
-
6
-
-
0025117392
-
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
-
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-30.
-
(1990)
Science
, vol.247
, pp. 824-830
-
-
Daley, G.Q.1
Van Etten, R.A.2
Baltimore, D.3
-
7
-
-
0029133211
-
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
-
Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371-8.
-
(1995)
Blood
, vol.86
, pp. 2371-2378
-
-
Gaiger, A.1
Henn, T.2
Hörth, E.3
Geissler, K.4
Mitterbauer, G.5
Maier-Dobersberger, T.6
-
8
-
-
77954977940
-
Chronic myeloid leukemia: Mechanisms of blastic transformation
-
Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120:2254-64.
-
(2010)
J Clin Invest
, vol.120
, pp. 2254-2264
-
-
Perrotti, D.1
Jamieson, C.2
Goldman, J.3
Skorski, T.4
-
9
-
-
67349233062
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
-
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61.
-
(2009)
Leukemia
, vol.23
, pp. 1054-1061
-
-
Hochhaus, A.1
O'Brien, S.G.2
Guilhot, F.3
Druker, B.J.4
Branford, S.5
Foroni, L.6
-
10
-
-
79955018499
-
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
-
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634-42.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1634-1642
-
-
Hehlmann, R.1
Lauseker, M.2
Jung-Munkwitz, S.3
Leitner, A.4
Müller, M.C.5
Pletsch, N.6
-
11
-
-
84867395848
-
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
-
Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-203.
-
(2012)
Leukemia
, vol.26
, pp. 2197-2203
-
-
Larson, R.A.1
Hochhaus, A.2
Hughes, T.P.3
Clark, R.E.4
Etienne, G.5
Kim, D.W.6
-
12
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
14
-
-
81555214617
-
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
-
Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565-72.
-
(2011)
Blood
, vol.118
, pp. 5565-5572
-
-
Chu, S.1
McDonald, T.2
Lin, A.3
Chakraborty, S.4
Huang, Q.5
Snyder, D.S.6
-
15
-
-
80053361301
-
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
-
Chomel J-C, Bonnet M-L, Sorel N, Bertrand A, Meunier M-C, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657-60.
-
(2011)
Blood
, vol.118
, pp. 3657-3660
-
-
Chomel, J.-C.1
Bonnet, M.-L.2
Sorel, N.3
Bertrand, A.4
Meunier, M.-C.5
Fichelson, S.6
-
16
-
-
84855842631
-
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
-
Shows that imatinib selects for persisting BCR-ABL-positive cells that express comparably low amounts of BCR-ABL mRNA and that these BCR-ABL low cells are not sensitive to TKI
-
• Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119:530-9. Shows that imatinib selects for persisting BCR-ABL-positive cells that express comparably low amounts of BCR-ABL mRNA and that these BCR-ABL low cells are not sensitive to TKI.
-
(2012)
Blood
, vol.119
, pp. 530-539
-
-
Kumari, A.1
Brendel, C.2
Hochhaus, A.3
Neubauer, A.4
Burchert, A.5
-
17
-
-
78650949272
-
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
-
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409.
-
(2011)
J Clin Invest
, vol.121
, pp. 396-409
-
-
Corbin, A.S.1
Agarwal, A.2
Loriaux, M.3
Cortes, J.4
Deininger, M.W.5
Druker, B.J.6
-
18
-
-
84863124648
-
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
-
Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501-10.
-
(2012)
Blood
, vol.119
, pp. 1501-1510
-
-
Hamilton, A.1
Helgason, G.V.2
Schemionek, M.3
Zhang, B.4
Myssina, S.5
Allan, E.K.6
-
19
-
-
84885085996
-
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
-
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J. Clin. Invest. 2013.
-
(2013)
J. Clin. Invest.
-
-
Neviani, P.1
Harb, J.G.2
Oaks, J.J.3
Santhanam, R.4
Walker, C.J.5
Ellis, J.J.6
-
20
-
-
4644341516
-
Discontinuation of imatinib therapy after achieving a molecular response [3]
-
DOI 10.1182/blood-2004-04-1335
-
Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204-5. (Pubitemid 39297882)
-
(2004)
Blood
, vol.104
, Issue.7
, pp. 2204-2205
-
-
Cortes, J.1
O'Brien, S.2
Kantarjian, H.3
-
21
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
-
Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-35.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.-X.1
Réa, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
22
-
-
84886917643
-
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
-
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515-22.
-
(2013)
Blood
, vol.122
, pp. 515-522
-
-
Ross, D.M.1
Branford, S.2
Seymour, J.F.3
Schwarer, A.P.4
Arthur, C.5
Yeung, D.T.6
-
23
-
-
34249988828
-
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
-
DOI 10.1182/blood-2006-06-032490
-
Modi H, McDonald T, Chu S, Yee J-K, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109:5411-21. (Pubitemid 46890564)
-
(2007)
Blood
, vol.109
, Issue.12
, pp. 5411-5421
-
-
Modi, H.1
McDonald, T.2
Chu, S.3
Yee, J.-K.4
Forman, S.J.5
Bhatia, R.6
-
24
-
-
84858835938
-
BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia
-
Chomel J-C, Sorel N, Guilhot J, Guilhot F, Turhan AG. BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood. 2012;119:2964-5.
-
(2012)
Blood
, vol.119
, pp. 2964-2965
-
-
Chomel, J.-C.1
Sorel, N.2
Guilhot, J.3
Guilhot, F.4
Turhan, A.G.5
-
25
-
-
84858807286
-
Response: Too much BCRABL to live on, but too little BCR-ABL to die on?
-
Burchert A, Neubauer A, Hochhaus A. Response: Too much BCRABL to live on, but too little BCR-ABL to die on? Blood. 2012;119:2965-6.
-
(2012)
Blood
, vol.119
, pp. 2965-2966
-
-
Burchert, A.1
Neubauer, A.2
Hochhaus, A.3
-
26
-
-
4544324306
-
Blasts from the past: New lessons in stem cell biology from chronic myelogenous leukemia
-
DOI 10.1016/j.ccr.2004.09.005, PII S1535610804002466
-
Huntly BJP, Gilliland DG. Blasts fromthe past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell. 2004;6:199-201. (Pubitemid 39222031)
-
(2004)
Cancer Cell
, vol.6
, Issue.3
, pp. 199-201
-
-
Huntly, B.J.P.1
Gilliland, D.G.2
-
27
-
-
36649002031
-
Loss of beta-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
-
DOI 10.1016/j.ccr.2007.11.003, PII S1535610807003340
-
Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528-41. (Pubitemid 350199070)
-
(2007)
Cancer Cell
, vol.12
, Issue.6
, pp. 528-541
-
-
Zhao, C.1
Blum, J.2
Chen, A.3
Kwon, H.Y.4
Jung, S.H.5
Cook, J.M.6
Lagoo, A.7
Reya, T.8
-
28
-
-
3943088431
-
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
-
DOI 10.1056/NEJMoa040258
-
Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-67. (Pubitemid 39063268)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.7
, pp. 657-667
-
-
Jamieson, C.H.M.1
Ailles, L.E.2
Dylla, S.J.3
Muijtjens, M.4
Jones, C.5
Zehnder, J.L.6
Gotlib, J.7
Li, K.8
Manz, M.G.9
Keating, A.10
Sawyers, C.L.11
Weissman, I.L.12
-
30
-
-
33646248661
-
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
-
Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. P Natl Acad Sci Usa. 2006;103:6688-93.
-
(2006)
P Natl Acad Sci Usa
, vol.103
, pp. 6688-6693
-
-
Williams, R.T.1
Roussel, M.F.2
Sherr, C.J.3
-
31
-
-
79960505838
-
A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia
-
Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D, et al. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 2011;118:390-400.
-
(2011)
Blood
, vol.118
, pp. 390-400
-
-
Chen, Y.1
Sullivan, C.2
Peng, C.3
Shan, Y.4
Hu, Y.5
Li, D.6
-
32
-
-
67649861052
-
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
-
Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41:783-92.
-
(2009)
Nat Genet
, vol.41
, pp. 783-792
-
-
Chen, Y.1
Hu, Y.2
Zhang, H.3
Peng, C.4
Li, S.5
-
33
-
-
0032211172
-
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
-
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-7. (Pubitemid 28492345)
-
(1998)
Blood
, vol.92
, Issue.9
, pp. 3362-3367
-
-
Bose, S.1
Deininger, M.2
Gora-Tybor, J.3
Goldman, J.M.4
Melo, J.V.5
-
34
-
-
0028786297
-
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
-
Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86:3118-22.
-
(1995)
Blood
, vol.86
, pp. 3118-3122
-
-
Biernaux, C.1
Loos, M.2
Sels, A.3
Huez, G.4
Stryckmans, P.5
-
36
-
-
0023410428
-
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
-
McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. P Natl Acad Sci Usa. 1987;84:6558-62.
-
(1987)
P Natl Acad Sci Usa
, vol.84
, pp. 6558-6562
-
-
McLaughlin, J.1
Chianese, E.2
Witte, O.N.3
-
37
-
-
0025209916
-
Acute leukaemia in bcr/abl transgenic mice
-
Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-3.
-
(1990)
Nature
, vol.344
, pp. 251-253
-
-
Heisterkamp, N.1
Jenster, G.2
Ten Hoeve, J.3
Zovich, D.4
Pattengale, P.K.5
Groffen, J.6
-
38
-
-
0032520986
-
Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210(bcr/abl): A novel transgenic model for human Ph-1-positive leukemias
-
HONDA H, Oda H, Suzuki T, Takahashi T, WITTE O, Ozawa K, et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210(bcr/abl): a novel transgenic model for human Ph-1-positive leukemias. Blood. 1998;91:2067-75.
-
(1998)
Blood
, vol.91
, pp. 2067-2075
-
-
Honda, H.1
Oda, H.2
Suzuki, T.3
Takahashi, T.4
Witte, O.5
Ozawa, K.6
-
39
-
-
0038240346
-
Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: Longer disease latency, thrombocytosis, and mild leukocytosis
-
DOI 10.1182/blood-2002-10-3182
-
Inokuchi K, Dan K, Takatori M, Takahuji H, Uchida N, Inami M, et al. Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. Blood. 2003;102:320-3. (Pubitemid 36759671)
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 320-323
-
-
Inokuchi, K.1
Dan, K.2
Takatori, M.3
Takahuji, H.4
Uchida, N.5
Inami, M.6
Miyake, K.7
Honda, H.8
Hirai, H.9
Shimada, T.10
-
40
-
-
0142183447
-
Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome
-
DOI 10.1182/blood-2003-03-0768
-
Huettner CS, Koschmieder S, Iwasaki H, Iwasaki-Arai J, Radomska HS, Akashi K, et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood. 2003;102:3363-70. (Pubitemid 37314779)
-
(2003)
Blood
, vol.102
, Issue.9
, pp. 3363-3370
-
-
Huettner, C.S.1
Koschmieder, S.2
Iwasaki, H.3
Iwasaki-Arai, J.4
Radomska, H.S.5
Akashi, K.6
Tenen, D.G.7
-
41
-
-
19944426030
-
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis
-
DOI 10.1182/blood-2003-12-4369
-
Koschmieder S, Göttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105:324-34. (Pubitemid 40053100)
-
(2005)
Blood
, vol.105
, Issue.1
, pp. 324-334
-
-
Koschmieder, S.1
Gottgens, B.2
Zhang, P.3
Iwasaki-Arai, J.4
Akashi, K.5
Kutok, J.L.6
Dayaram, T.7
Geary, K.8
Green, A.R.9
Tenen, D.G.10
Huettner, C.S.11
-
42
-
-
84885846261
-
Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia
-
First transgenic mouse, in which BCR-ABL is expressed from the enogenous BCR promoter. Supports the concept that BCR-ABL may require cooperating events to induce transformation
-
• Foley SB, Hildenbrand ZL, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI, et al. Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia. Cell Rep. 2013;5:51-60. First transgenic mouse, in which BCR-ABL is expressed from the enogenous BCR promoter. Supports the concept that BCR-ABL may require cooperating events to induce transformation.
-
(2013)
Cell Rep
, vol.5
, pp. 51-60
-
-
Foley, S.B.1
Hildenbrand, Z.L.2
Soyombo, A.A.3
Magee, J.A.4
Wu, Y.5
Oravecz-Wilson, K.I.6
-
43
-
-
7744220635
-
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
-
DOI 10.1038/nature03043
-
Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112-7. (Pubitemid 39472236)
-
(2004)
Nature
, vol.431
, Issue.7012
, pp. 1112-1117
-
-
Shachaf, C.M.1
Kopelman, A.M.2
Arvanitis, C.3
Karlsson, A.4
Beer, S.5
Mandl, S.6
Bachmann, M.H.7
Borowsky, A.D.8
Ruebner, B.9
Cardiff, R.D.10
Yang, Q.11
Bishop, J.M.12
Contag, C.H.13
Felsher, D.W.14
-
44
-
-
10944258521
-
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation
-
DOI 10.1016/j.ccr.2004.10.013, PII S1535610804003071
-
Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6:577-86. (Pubitemid 40017701)
-
(2004)
Cancer Cell
, vol.6
, Issue.6
, pp. 577-586
-
-
Boxer, R.B.1
Jang, J.W.2
Sintasath, L.3
Chodosh, L.A.4
-
45
-
-
0038107350
-
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations
-
DOI 10.1182/blood-2002-10-3091
-
Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003;101:2797-803. (Pubitemid 36857646)
-
(2003)
Blood
, vol.101
, Issue.7
, pp. 2797-2803
-
-
Karlsson, A.1
Giuriato, S.2
Tang, F.3
Fung-Weier, J.4
Levan, G.5
Felsher, D.W.6
-
46
-
-
10944228766
-
Oncogene addiction: Sometimes a temporary slavery
-
DOI 10.1016/j.ccr.2004.12.002, PII S1535610804003393
-
Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004;6:535-8. (Pubitemid 40017696)
-
(2004)
Cancer Cell
, vol.6
, Issue.6
, pp. 535-538
-
-
Jonkers, J.1
Berns, A.2
-
47
-
-
17244366865
-
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
-
DOI 10.1038/nature03485
-
Gorgoulis VG, Vassiliou L-VF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-13. (Pubitemid 40559004)
-
(2005)
Nature
, vol.434
, Issue.7035
, pp. 907-913
-
-
Gorgoulis, V.G.1
Vassiliou, L.-V.F.2
Karakaidos, P.3
Zacharatos, P.4
Kotsinas, A.5
Liloglou, T.6
Venere, M.7
DiTullio Jr., R.A.8
Kastrinakis, N.G.9
Levy, B.10
Kletsas, D.11
Yoneta, A.12
Herlyn, M.13
Kittas, C.14
Halazonetis, T.D.15
-
48
-
-
23244461708
-
Oncogene-induced senescence as an initial barrier in lymphoma development
-
DOI 10.1038/nature03841
-
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436:660-5. (Pubitemid 41117262)
-
(2005)
Nature
, vol.436
, Issue.7051
, pp. 660-665
-
-
Braig, M.1
Lee, S.2
Loddenkemper, C.3
Rudolph, C.4
Peters, A.H.F.M.5
Schlegelberger, B.6
Stein, H.7
Dorken, B.8
Jenuwein, T.9
Schmitt, C.A.10
-
49
-
-
17244367849
-
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
-
DOI 10.1038/nature03482
-
Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864-70. (Pubitemid 40558993)
-
(2005)
Nature
, vol.434
, Issue.7035
, pp. 864-870
-
-
Bartkova, J.1
Horejsi, Z.2
Koed, K.3
Kramer, A.4
Tort, F.5
Zleger, K.6
Guldberg, P.7
Sehested, M.8
Nesland, J.M.9
Lukas, C.10
Orntoft, T.11
Lukas, J.12
Bartek, J.13
-
50
-
-
33845235459
-
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
-
DOI 10.1038/nature05268, PII NATURE05268
-
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444: 633-7. (Pubitemid 44864442)
-
(2006)
Nature
, vol.444
, Issue.7119
, pp. 633-637
-
-
Bartkova, J.1
Rezaei, N.2
Liontos, M.3
Karakaidos, P.4
Kletsas, D.5
Issaeva, N.6
Vassiliou, L.-V.F.7
Kolettas, E.8
Niforou, K.9
Zoumpourlis, V.C.10
Takaoka, M.11
Nakagawa, H.12
Tort, F.13
Fugger, K.14
Johansson, F.15
Sehested, M.16
Andersen, C.L.17
Dyrskjot, L.18
Orntoft, T.19
Lukas, J.20
Kittas, C.21
Helleday, T.22
Halazonetis, T.D.23
Bartek, J.24
Gorgoulis, V.G.25
more..
-
51
-
-
40449120350
-
An oncogene-induced DNA damage model for cancer development
-
DOI 10.1126/science.1140735
-
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352-5. (Pubitemid 351354863)
-
(2008)
Science
, vol.319
, Issue.5868
, pp. 1352-1355
-
-
Halazonetis, T.D.1
Gorgoulis, V.G.2
Bartek, J.3
-
52
-
-
33845269825
-
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
-
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638-42.
-
(2006)
Nature
, vol.444
, pp. 638-642
-
-
Di Micco, R.1
Fumagalli, M.2
Cicalese, A.3
Piccinin, S.4
Gasparini, P.5
Luise, C.6
-
53
-
-
0030944985
-
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a)
-
DOI 10.1016/S0092-8674(00)81902-9
-
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593-602. (Pubitemid 27152402)
-
(1997)
Cell
, vol.88
, Issue.5
, pp. 593-602
-
-
Serrano, M.1
Lin, A.W.2
McCurrach, M.E.3
Beach, D.4
Lowe, S.W.5
-
54
-
-
9244224723
-
Intrinsic tumour suppression
-
DOI 10.1038/nature03098
-
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307-15. (Pubitemid 39551658)
-
(2004)
Nature
, vol.432
, Issue.7015
, pp. 307-315
-
-
Lowe, S.W.1
Cepero, E.2
Evan, G.3
-
55
-
-
0030728468
-
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF)
-
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649-59. (Pubitemid 27513656)
-
(1997)
Cell
, vol.91
, Issue.5
, pp. 649-659
-
-
Kamijo, T.1
Zindy, F.2
Roussel, M.F.3
Quelle, D.E.4
Downing, J.R.5
Ashmun, R.A.6
Grosveld, G.7
Sherr, C.J.8
-
56
-
-
0032145569
-
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
-
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424-33. (Pubitemid 28371361)
-
(1998)
Genes and Development
, vol.12
, Issue.15
, pp. 2424-2433
-
-
Zindy, F.1
Eischen, C.M.2
Randle, D.H.3
Kamijo, T.4
Cleveland, J.L.5
Sherr, C.J.6
Roussel, M.F.7
-
58
-
-
0025917065
-
p53 in chronic myelogenous leukemia in acute phase
-
Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, et al. p53 in chronic myelogenous leukemia in acute phase. P Natl Acad Sci Usa. 1991;88:6293-7. (Pubitemid 21914932)
-
(1991)
Proceedings of the National Academy of Sciences of the United States of America
, vol.88
, Issue.14
, pp. 6293-6297
-
-
Feinstein, E.1
Cimino, G.2
Gale, R.P.3
Alimena, G.4
Berthier, R.5
Kishi, K.6
Goldman, J.7
Zaccaria, A.8
Berrebi, A.9
Canaani, E.10
-
59
-
-
84863011183
-
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stemcells in combination with imatinib
-
Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stemcells in combination with imatinib. Cancer Cell. 2012;21:266-81.
-
(2012)
Cancer Cell
, vol.21
, pp. 266-281
-
-
Li, L.1
Wang, L.2
Li, L.3
Wang, Z.4
Ho, Y.5
McDonald, T.6
-
60
-
-
77951667031
-
Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway
-
Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis. 2010;15:608-20.
-
(2010)
Apoptosis
, vol.15
, pp. 608-620
-
-
Kurosu, T.1
Wu, N.2
Oshikawa, G.3
Kagechika, H.4
Miura, O.5
-
61
-
-
79955830260
-
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
-
Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25:761-9.
-
(2011)
Leukemia
, vol.25
, pp. 761-769
-
-
Peterson, L.F.1
Mitrikeska, E.2
Giannola, D.3
Lui, Y.4
Sun, H.5
Bixby, D.6
-
62
-
-
13944273471
-
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
-
DOI 10.1038/ncb1211
-
Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005;7:165-71. (Pubitemid 40268131)
-
(2005)
Nature Cell Biology
, vol.7
, Issue.2
, pp. 165-171
-
-
Lin, T.1
Chao, C.2
Saito, S.3
Mazur, S.J.4
Murphy, M.E.5
Appella, E.6
Xu, Y.7
-
63
-
-
0037711685
-
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice
-
DOI 10.1016/S0301-472X(03)00072-9
-
TeKippe M, Harrison DE, Chen J. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol. 2003;31:521-7. (Pubitemid 36793959)
-
(2003)
Experimental Hematology
, vol.31
, Issue.6
, pp. 521-527
-
-
TeKippe, M.1
Harrison, D.E.2
Chen, J.3
-
64
-
-
43449084346
-
Arf-/- multipotent progenitors
-
DOI 10.1038/nature06869, PII NATURE06869
-
Akala OO, Park I-K, Qian D, Pihalja M, Becker MW, Clarke MF. Long-term haematopoietic reconstitution by Trp53-/- p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature. 2008;453:228-32. (Pubitemid 351667977)
-
(2008)
Nature
, vol.453
, Issue.7192
, pp. 228-232
-
-
Akala, O.O.1
Park, I.-K.2
Qian, D.3
Pihalja, M.4
Becker, M.W.5
Clarke, M.F.6
-
65
-
-
58049216794
-
p53 regulates hematopoietic stem cell quiescence
-
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4:37-48.
-
(2009)
Cell Stem Cell
, vol.4
, pp. 37-48
-
-
Liu, Y.1
Elf, S.E.2
Miyata, Y.3
Sashida, G.4
Liu, Y.5
Huang, G.6
-
66
-
-
69349098834
-
Stem cells: The promises and perils of p53
-
Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature. 2009;460:1085-6.
-
(2009)
Nature
, vol.460
, pp. 1085-1086
-
-
Krizhanovsky, V.1
Lowe, S.W.2
-
67
-
-
0033552813
-
The oncogene and Polycombgroup gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
-
DOI 10.1038/16476
-
Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-8. (Pubitemid 29050921)
-
(1999)
Nature
, vol.397
, Issue.6715
, pp. 164-168
-
-
Jacobs, J.L.1
Kieboom, K.2
Marino, S.3
DePinho, R.A.4
Van Lohuizen, M.5
-
68
-
-
0038349957
-
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
-
DOI 10.1038/nature01587
-
Park I-K, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423:302-5. (Pubitemid 40852701)
-
(2003)
Nature
, vol.423
, Issue.6937
, pp. 302-305
-
-
Park, I.-K.1
Qian, D.2
Kiel, M.3
Becker, M.W.4
Pihalja, M.5
Weissman, I.L.6
Morrison, S.J.7
Clarke, M.F.8
-
69
-
-
44849129491
-
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
-
DOI 10.1101/gad.1673908
-
Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22:1411-5. (Pubitemid 351793074)
-
(2008)
Genes and Development
, vol.22
, Issue.11
, pp. 1411-1415
-
-
Mullighan, C.G.1
Williams, R.T.2
Downing, J.R.3
Sherr, C.J.4
-
70
-
-
0037458609
-
A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells
-
DOI 10.1074/jbc.M211562200
-
Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S, et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem. 2003;278:6411-9. (Pubitemid 36800899)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.8
, pp. 6411-6419
-
-
Komatsu, N.1
Watanabe, T.2
Uchida, M.3
Mori, M.4
Kirito, K.5
Kikuchi, S.6
Liu, Q.7
Tauchi, T.8
Miyazawa, K.9
Endo, H.10
Nagai, T.11
Ozawa, K.12
-
71
-
-
0037975597
-
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor
-
DOI 10.1073/pnas.0731871100
-
Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. P Natl Acad Sci Usa. 2003;100:6523-8. (Pubitemid 36666614)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.11
, pp. 6523-6528
-
-
Ghaffari, S.1
Jagani, Z.2
Kitidis, C.3
Lodish, H.F.4
Khosravi-Far, R.5
-
72
-
-
76249087423
-
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
-
Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676-80.
-
(2010)
Nature
, vol.463
, pp. 676-680
-
-
Naka, K.1
Hoshii, T.2
Muraguchi, T.3
Tadokoro, Y.4
Ooshio, T.5
Kondo, Y.6
-
73
-
-
80055108071
-
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
-
This article shows that bcl-6 limits tumorsuppressive responses by transcriptional suppression of p53 and Arf in a CML mouse model
-
• Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim Y-M, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208:2163-74. This article shows that bcl-6 limits tumorsuppressive responses by transcriptional suppression of p53 and Arf in a CML mouse model.
-
(2011)
J Exp Med
, vol.208
, pp. 2163-2174
-
-
Hurtz, C.1
Hatzi, K.2
Cerchietti, L.3
Braig, M.4
Park, E.5
Kim, Y.-M.6
-
74
-
-
79956305728
-
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
-
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011;473:384-8.
-
(2011)
Nature
, vol.473
, pp. 384-388
-
-
Duy, C.1
Hurtz, C.2
Shojaee, S.3
Cerchietti, L.4
Geng, H.5
Swaminathan, S.6
-
75
-
-
84863116364
-
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
-
Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012;119:1904-14.
-
(2012)
Blood
, vol.119
, pp. 1904-1914
-
-
Yuan, H.1
Wang, Z.2
Li, L.3
Zhang, H.4
Modi, H.5
Horne, D.6
-
76
-
-
84873441292
-
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
-
Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. P Natl Acad Sci Usa. 2013;110:1999-2004.
-
(2013)
P Natl Acad Sci Usa
, vol.110
, pp. 1999-2004
-
-
Tomasetti, C.1
Vogelstein, B.2
Parmigiani, G.3
-
77
-
-
34249676964
-
Chronic myeloid leukaemia as a model of disease evolution in human cancer
-
DOI 10.1038/nrc2147, PII NRC2147
-
Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-53. (Pubitemid 46823444)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.6
, pp. 441-453
-
-
Melo, J.V.1
Barnes, D.J.2
-
78
-
-
33644525274
-
Gene expression changes associated with progression and response in chronic myeloid leukemia
-
Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. P Natl Acad Sci Usa. 2006;103:2794-9.
-
(2006)
P Natl Acad Sci Usa
, vol.103
, pp. 2794-2799
-
-
Radich, J.P.1
Dai, H.2
Mao, M.3
Oehler, V.4
Schelter, J.5
Druker, B.6
-
79
-
-
43049139905
-
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
-
DOI 10.1038/nature06866, PII NATURE06866
-
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-4. (Pubitemid 351630327)
-
(2008)
Nature
, vol.453
, Issue.7191
, pp. 110-114
-
-
Mullighan, C.G.1
Miller, C.B.2
Radtke, I.3
Phillips, L.A.4
Dalton, J.5
Ma, J.6
White, D.7
Hughes, T.P.8
Le, B.M.M.9
Pui, C.-H.10
Relling, M.V.11
Shurtleff, S.A.12
Downing, J.R.13
-
80
-
-
34247897276
-
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
-
DOI 10.1038/ncb1567, PII NCB1567
-
Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9:493-505. (Pubitemid 46696530)
-
(2007)
Nature Cell Biology
, vol.9
, Issue.5
, pp. 493-505
-
-
Sarkisian, C.J.1
Keister, B.A.2
Stairs, D.B.3
Boxer, R.B.4
Moody, S.E.5
Chodosh, L.A.6
-
81
-
-
56849093474
-
Distinct thresholds govern Myc's biological output in vivo
-
As one of three earlier publications it shows that oncogene levels critically determine biological output. Whereas high oncogene level lead to engagement of tumor suppressive barriers low level don't. This suggests that the maintenance of low level oncogenic activity is tumor suppressive
-
•• Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008;14:447-57. As one of three earlier publications it shows that oncogene levels critically determine biological output. Whereas high oncogene level lead to engagement of tumor suppressive barriers low level don't. This suggests that the maintenance of low level oncogenic activity is tumor suppressive.
-
(2008)
Cancer Cell
, vol.14
, pp. 447-457
-
-
Murphy, D.J.1
Junttila, M.R.2
Pouyet, L.3
Karnezis, A.4
Shchors, K.5
Bui, D.A.6
-
82
-
-
78649492693
-
Selective activation of p53-mediated tumour suppression in high-grade tumours
-
Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010;468:567-71.
-
(2010)
Nature
, vol.468
, pp. 567-571
-
-
Junttila, M.R.1
Karnezis, A.N.2
Garcia, D.3
Madriles, F.4
Kortlever, R.M.5
Rostker, F.6
-
83
-
-
0037025173
-
Cancer: Addiction to oncogenes - The Achilles heal of cancer
-
DOI 10.1126/science.1073096
-
Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002;297:63-4. (Pubitemid 34743088)
-
(2002)
Science
, vol.297
, Issue.5578
, pp. 63-64
-
-
Weinstein, I.B.1
-
84
-
-
84055179140
-
Chronic myeloid leukemia stem cells in the era of targeted therapies: Resistance, persistence and long-term dormancy
-
Chomel J-C, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2:713-27.
-
(2011)
Oncotarget
, vol.2
, pp. 713-727
-
-
Chomel, J.-C.1
Turhan, A.G.2
-
85
-
-
77958000220
-
Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
-
Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, et al. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia. 2010;24:1817-21.
-
(2010)
Leukemia
, vol.24
, pp. 1817-1821
-
-
Grant, H.1
Jiang, X.2
Stebbing, J.3
Foroni, L.4
Craddock, C.5
Griffiths, M.6
-
86
-
-
34249693090
-
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
-
DOI 10.1093/jnci/djk150
-
Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronicmyeloid leukemia stem cells. J Natl Cancer Inst. 2007;99:680-93. (Pubitemid 47073530)
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.9
, pp. 680-693
-
-
Jiang, X.1
Saw, K.M.2
Eaves, A.3
Eaves, C.4
-
87
-
-
77957196195
-
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
-
Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C, et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010;116:2112-21.
-
(2010)
Blood
, vol.116
, pp. 2112-2121
-
-
Jiang, X.1
Forrest, D.2
Nicolini, F.3
Turhan, A.4
Guilhot, J.5
Yip, C.6
-
88
-
-
0036090222
-
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
-
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-25.
-
(2002)
Blood
, vol.99
, pp. 319-325
-
-
Graham, S.M.1
Jørgensen, H.G.2
Allan, E.3
Pearson, C.4
Alcorn, M.J.5
Richmond, L.6
-
89
-
-
34247329753
-
+ CML cells
-
DOI 10.1182/blood-2006-11-057521
-
Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016-9. (Pubitemid 46641755)
-
(2007)
Blood
, vol.109
, Issue.9
, pp. 4016-4019
-
-
Jorgensen, H.G.1
Allan, E.K.2
Jordanides, N.E.3
Mountford, J.C.4
Holyoake, T.L.5
-
90
-
-
33744486584
-
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
-
DOI 10.1182/blood-2005-07-2947
-
Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532-9. (Pubitemid 43801382)
-
(2006)
Blood
, vol.107
, Issue.11
, pp. 4532-4539
-
-
Copland, M.1
Hamilton, A.2
Elrick, L.J.3
Baird, J.W.4
Allan, E.K.5
Jordanides, N.6
Barow, M.7
Mountford, J.C.8
Holyoake, T.L.9
-
91
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734-9.
-
(2010)
N Engl J Med
, vol.363
, pp. 1734-1739
-
-
Choi, Y.L.1
Soda, M.2
Yamashita, Y.3
Ueno, T.4
Takashima, J.5
Nakajima, T.6
-
92
-
-
84869090342
-
High activity of sorafenib in FLT3-ITD-positive acutemyeloid leukemia synergizes with allo-immune effects to induce sustained responses
-
Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, et al. High activity of sorafenib in FLT3-ITD-positive acutemyeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012.
-
(2012)
Leukemia
-
-
Metzelder, S.K.1
Schroeder, T.2
Finck, A.3
Scholl, S.4
Fey, M.5
Götze, K.6
|